198 related articles for article (PubMed ID: 17078596)
1. [Are the NSAIDs able to compromising the cardio-preventive efficacy of aspirin?].
Flipo RM
Presse Med; 2006 Sep; 35(9 Spec No 1):1S53-60. PubMed ID: 17078596
[TBL] [Abstract][Full Text] [Related]
2. [Are the NSAIDs able to compromising the cardio-preventive efficacy of aspirin?].
Flipo RM
Presse Med; 2006 Sep; 35 Suppl 1():53-60. PubMed ID: 17870554
[TBL] [Abstract][Full Text] [Related]
3. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
Farkouh ME; Kirshner H; Harrington RA; Ruland S; Verheugt FW; Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Gimona A; Matchaba P; Hawkey CJ; Chesebro JH;
Lancet; 2004 Aug 21-27; 364(9435):675-84. PubMed ID: 15325832
[TBL] [Abstract][Full Text] [Related]
4. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population.
García Rodríguez LA; Varas-Lorenzo C; Maguire A; González-Pérez A
Circulation; 2004 Jun; 109(24):3000-6. PubMed ID: 15197149
[TBL] [Abstract][Full Text] [Related]
5. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
Maree AO; Fitzgerald DJ
Circulation; 2007 Apr; 115(16):2196-207. PubMed ID: 17452618
[No Abstract] [Full Text] [Related]
6. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study.
Meek IL; Vonkeman HE; Kasemier J; Movig KL; van de Laar MA
Eur J Clin Pharmacol; 2013 Mar; 69(3):365-71. PubMed ID: 22890587
[TBL] [Abstract][Full Text] [Related]
7. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
Angiolillo DJ; Hwang C; Datto C; Desai B; Sostek M
Clin Ther; 2011 Dec; 33(12):1883-93. PubMed ID: 22078153
[TBL] [Abstract][Full Text] [Related]
8. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Matchaba P; Gimona A; Hawkey CJ;
Lancet; 2004 Aug 21-27; 364(9435):665-74. PubMed ID: 15325831
[TBL] [Abstract][Full Text] [Related]
9. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
Strand V
Lancet; 2007 Dec; 370(9605):2138-51. PubMed ID: 18156036
[TBL] [Abstract][Full Text] [Related]
10. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs--pharmacological mechanisms and clinical relevance.
Hohlfeld T; Saxena A; Schrör K
Thromb Haemost; 2013 May; 109(5):825-33. PubMed ID: 23238666
[TBL] [Abstract][Full Text] [Related]
11. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
12. Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis.
Gengo FM; Rubin L; Robson M; Rainka M; Gengo MF; Mager DE; Bates V
J Clin Pharmacol; 2008 Jan; 48(1):117-22. PubMed ID: 18094224
[TBL] [Abstract][Full Text] [Related]
13. Aspirin and cyclooxygenase-2 inhibitors.
Armstrong TA
Am J Health Syst Pharm; 2003 Jul; 60(14):1481. PubMed ID: 12892035
[No Abstract] [Full Text] [Related]
14. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
Farkouh ME; Greenberg JD; Jeger RV; Ramanathan K; Verheugt FW; Chesebro JH; Kirshner H; Hochman JS; Lay CL; Ruland S; Mellein B; Matchaba PT; Fuster V; Abramson SB
Ann Rheum Dis; 2007 Jun; 66(6):764-70. PubMed ID: 17412741
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
Catella-Lawson F; Reilly MP; Kapoor SC; Cucchiara AJ; DeMarco S; Tournier B; Vyas SN; FitzGerald GA
N Engl J Med; 2001 Dec; 345(25):1809-17. PubMed ID: 11752357
[TBL] [Abstract][Full Text] [Related]
16. Aspirin, NSAIDs, and cardiovascular risk: is there a link?
Kapoor JR
Am J Med; 2008 Nov; 121(11):e9. PubMed ID: 18954833
[No Abstract] [Full Text] [Related]
17. The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding.
Konstantinopoulos PA; Lehmann DF
J Clin Pharmacol; 2005 Jul; 45(7):742-50. PubMed ID: 15951464
[TBL] [Abstract][Full Text] [Related]
18. Comparative antiplatelet activity of COX1 NSAIDS versus aspirin, encompassing regimen simplification and gastroprotection: a call for a controlled study.
Rothschild BM
Reumatismo; 2004; 56(2):89-93. PubMed ID: 15309216
[TBL] [Abstract][Full Text] [Related]
19. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin.
Schiff M; Hochberg MC; Oldenhof J; Brune K
Curr Med Res Opin; 2009 Oct; 25(10):2471-7. PubMed ID: 19678751
[TBL] [Abstract][Full Text] [Related]
20. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study.
Ray WA; Stein CM; Hall K; Daugherty JR; Griffin MR
Lancet; 2002 Jan; 359(9301):118-23. PubMed ID: 11809254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
